Condition: Relapsed/Refractory Multiple Myeloma · Sponsor: BeOne Medicines
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14). The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.
This description comes directly from the study's public registry record.
BeOne Medicines · 1.877.828.5568 · clinicaltrials@beonemed.com
Always discuss trial participation with your own doctor first.
| University of Alabama At Birmingham Hospital | Birmingham, Alabama, United States | Recruiting |
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| City of Hope Irvine Lennar | Irvine, California, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Emory University Winship Cancer Center | Atlanta, Georgia, United States | Recruiting |
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Completed |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Hackensack University Medical Center | Hackensack, New Jersey, United States | Recruiting |
| Weill Cornell Medical College Newyork Presbyterian Hospital | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center Mskcc | New York, New York, United States | Recruiting |
| The James Cancer Hospital and Solove Research Institute At Ohio State University | Columbus, Ohio, United States | Recruiting |
+ 72 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04973605